Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-6. (canceled)

7. (Currently amended) The method of claim 50 ~~52~~, wherein said therapeutic composition further comprises a recombinant nucleic acid molecule having a nucleic acid sequence encoding a ~~said cytokine is selected from the group consisting of~~ hematopoietic growth factors, an interleukins, an interferons, an immunoglobulin superfamily molecules, a tumor necrosis factor family molecules ~~and~~, or a chemokines said nucleic acid sequence being operatively linked to a transcription control sequence.

8. (Withdrawn) The method of claim 52, wherein said cytokine is an interleukin.

9. (Previously presented) The method of claim 52, wherein said cytokine is selected from the group consisting of interleukin-2, interleukin-7, interleukin-12, interleukin-15, interleukin-18, and interferon-γ.

10. (Previously presented) The method of claim 52, wherein said cytokine is selected from the group consisting of interleukin-2, interleukin-12, interleukin-18, and interferon-γ.

11. (Previously presented) The method of claim 52, wherein said transcription control sequences are selected from the group consisting of Rous sarcoma virus (RSV) control sequences, cytomegalovirus (CMV) control sequences, adenovirus control sequences and Simian virus (SV-40) control sequences.

12. (Previously presented) The method of claim 50, wherein said liposome delivery vehicle comprises lipids selected from the group consisting of multilamellar vesicle lipids and extruded lipids.

13. (Previously presented) The method of claim 50, wherein said liposome delivery vehicle comprises multilamellar vesicle lipids.

14. (Previously presented) The method of claim 50, wherein said liposome delivery vehicle comprises cationic liposomes.

15. (Previously presented) The method of claim 50, wherein said liposome delivery vehicle comprises pairs of lipids selected from the group consisting of DOTMA and cholesterol; DOTAP and cholesterol; DOTIM and cholesterol; and DDAB and cholesterol.

16. (Previously presented) The method of claim 50, wherein said liposome delivery vehicle comprises DOTAP and cholesterol.

17. (Currently amended) The method of claim 27~~5~~0, wherein expression of said RNA in a tissue of said mammal elicits said tumor antigen-specific immune response in said mammal.

18. (Previously presented) The method of claim 50, wherein administering said RNA and said liposome elicit said systemic, non-specific immune response in said mammal.

19. (Previously presented) The method of claim 50, wherein said mammal is selected from the from the group consisting of humans, dogs, cats, mice, rats, sheep, cattle, horses and pigs.

20. (Previously presented) The method of claim 50, wherein said mammal is a human.

21-23. (canceled)

24. (Currently amended) The method of claim 2750, wherein said total RNA is isolated from an autologous tumor sample.

25. (Currently amended) A method to elicit a tumor antigen-specific immune response and a systemic, non-specific immune response in a mammal that has cancer, comprising administering to the mammal a therapeutic composition by a route of administration selected from the group consisting of intravenous and intraperitoneal administration, said therapeutic composition comprising:

(a) a liposome delivery vehicle; and,

(b) total RNA isolated from a tumor sample, said RNA encoding tumor antigens ~~The method of claim 50~~, wherein said total RNA is isolated from a plurality of allogeneic tumor samples of the same histological tumor type.

26. (Currently amended) The method of claim 2550, wherein said cancer is selected from the group consisting of melanomas, squamous cell carcinoma, breast cancers, head and neck carcinomas, thyroid carcinomas, soft tissue sarcomas, bone sarcomas, testicular cancers, prostatic cancers, ovarian cancers, bladder cancers, skin cancers, brain cancers, angiosarcomas, hemangiosarcomas, mast cell tumors, primary hepatic cancers, lung cancers, pancreatic cancers, gastrointestinal cancers, renal cell carcinomas, hematopoietic neoplasias, and metastatic cancers thereof.

27. (Currently amended) A method to elicit a tumor antigen-specific immune response and a systemic, non-specific immune response in a mammal that has cancer, comprising administering to the mammal a therapeutic composition by a route of administration selected from the group consisting of intravenous and intraperitoneal administration, said therapeutic composition comprising:

(a) a liposome delivery vehicle; and,

(b) total RNA isolated from a tumor sample, said RNA encoding tumor antigens ~~The method of claim 50~~, wherein said cancer is selected from the group consisting of a primary lung cancer and a pulmonary metastatic cancer.

28. (Currently amended) The method of claim 25~~50~~, wherein said tumor antigen is from a cancer selected from the group consisting of melanomas, squamous cell carcinoma, breast cancers, head and neck carcinomas, thyroid carcinomas, soft tissue sarcomas, bone sarcomas, testicular cancers, prostatic cancers, ovarian cancers, bladder cancers, skin cancers, brain cancers, angiosarcomas, hemangiosarcomas, mast cell tumors, primary hepatic cancers, lung cancers, pancreatic cancers, gastrointestinal cancers, renal cell carcinomas, hematopoietic neoplasias and metastatic cancers thereof.

29. (Currently amended) The method of claim 27~~50~~, wherein said tumor antigen is selected from the group consisting of tumor antigens having epitopes that are recognized by T cells, tumor antigens having epitopes that are recognized by B cells, tumor antigens that are exclusively expressed by tumor cells; and tumor antigens that are expressed by tumor cells and by non-tumor cells.

30. (Currently amended) The method of claim 27~~50~~, wherein said administering produces a result selected from the group consisting of alleviation of said cancer, reduction of size of a tumor associated with said cancer, ~~elimination of a tumor associated with said cancer, prevention of metastatic cancer, prevention of said cancer~~ and stimulation of effector cell immunity against said cancer.

31. (Currently amended) The method of claim 27~~50~~, wherein said administration of said composition by an intravenous route ~~prevents~~ inhibits an increase in size of said pulmonary metastatic cancer in said mammal.

32-49. (canceled)

50. (Currently amended) A method to elicit a ~~tumor antigen-specific immune response and a~~ systemic, non-specific immune response in a mammal ~~that has cancer~~, comprising administering to [[a]] the mammal a therapeutic composition by a route of administration selected from the group consisting of intravenous and intraperitoneal administration, said therapeutic composition comprising:

(a) a liposome delivery vehicle; and,

(b) ~~total~~ non-coding RNA ~~isolated from a tumor sample, said RNA encoding tumor antigens~~.

51. (Original) The method of claim 50, wherein said route of administration is intravenous.

52. (Original) The method of claim 50, wherein said therapeutic composition further comprises a recombinant nucleic acid molecule having a nucleic acid sequence encoding a cytokine, said nucleic acid sequence being operatively linked to a transcription control sequence.

53. (Currently amended) The method of claim 27~~50~~, wherein said RNA is enriched for poly-A RNA prior to said administration to said mammal.

54-55. (canceled)

56. (Currently amended) A composition for systemic administration to a ~~cancer afflicted~~ mammal by intravenous or intraperitoneal administration to elicit ~~a tumor antigen-specific immune response and~~ a systemic, non-specific immune response, said composition comprising:

(a) a liposome delivery vehicle; and

(b) ~~total~~ non-coding RNA ~~isolated from a tumor sample, said RNA encoding tumor antigens~~.

57. (Previously presented) The composition of claim 56, wherein said liposome delivery vehicle comprises lipids selected from the group consisting of multilamellar vesicle lipids and extruded lipids.

58. (Previously presented) The composition of claim 56, wherein said composition has a nucleic acid:lipid ratio of from about 1:10 to about 1:40.

59. (Original) The composition of claim 56, wherein said liposome comprises multilamellar vesicle lipids.

60. (Original) The composition of claim 56, wherein said liposome delivery vehicle comprises cationic liposomes.

61. (Original) The composition of claim 56, wherein said liposome delivery vehicle comprises pairs of lipids selected from the group consisting of DOTMA and cholesterol; DOTAP and cholesterol; DOTIM and cholesterol; and DDAB and cholesterol.

62. (Previously presented) The composition of claim 56, wherein said liposome delivery vehicle comprises DOTIM and cholesterol.

63. (Original) The composition of claim 56, further comprising a pharmaceutically acceptable excipient.

64. (Original) The composition of claim 63, wherein said excipient comprises a non-ionic diluent.

65. (Original) The composition of claim 64, wherein said excipient is 5 percent dextrose in water (D5W).

66. (Currently amended) The method of claim 27~~50~~, wherein said total RNA is isolated from an autologous tumor sample and said method further comprising converting said total RNA into ~~in the form of~~ a plurality of cDNA sequences amplified from said total RNA, and

operatively linking each of said cDNA sequences ~~being operatively linked~~ to a transcription control sequence.

67. (Currently amended) The method of claim 27~~50~~, wherein said total RNA is isolated from a plurality of allogeneic tumor samples of the same histological tumor type and said method further comprising converting said total RNA into ~~in the form of~~ a plurality of cDNA sequences amplified from said total RNA and operatively linking, each of said cDNA sequences ~~being operatively linked~~ to a transcription control sequence.